These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The effect of disease activity related cytokines on the fibrinolytic potential and cICAM-1 expression in rheumatoid arthritis. Kamper EF; Kopeikina LT; Trontzas P; Potamianou A; Tsiroglou E; Stavridis JC J Rheumatol; 2000 Nov; 27(11):2545-50. PubMed ID: 11093432 [TBL] [Abstract][Full Text] [Related]
3. [Activation of fibrynolysis in children with chronic B or C hepatitis]. Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691 [TBL] [Abstract][Full Text] [Related]
4. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma. Sørensen JV Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044 [TBL] [Abstract][Full Text] [Related]
5. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes. Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392 [TBL] [Abstract][Full Text] [Related]
6. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954 [TBL] [Abstract][Full Text] [Related]
7. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Agren A; Wiman B; Schulman S Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953 [TBL] [Abstract][Full Text] [Related]
8. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Raaphorst J; Johan Groeneveld AB; Bossink AW; Erik Hack C Thromb Haemost; 2001 Aug; 86(2):543-9. PubMed ID: 11522001 [TBL] [Abstract][Full Text] [Related]
9. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. Wållberg-Jonsson S; Cvetkovic JT; Sundqvist KG; Lefvert AK; Rantapää-Dahlqvist S J Rheumatol; 2002 May; 29(5):875-82. PubMed ID: 12022343 [TBL] [Abstract][Full Text] [Related]
10. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547 [TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis system in patients with bronchial asthma. Banach-Wawrzeńczyk E; Dziedziczko A; Rość D Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294 [TBL] [Abstract][Full Text] [Related]
12. Elastase- and plasmin-mediated fibrinolysis in rheumatoid arthritis. Carmassi F; De Negri F; Morale M; Puccetti R; Chung SI Int J Tissue React; 1994; 16(2):89-93. PubMed ID: 7960505 [TBL] [Abstract][Full Text] [Related]
13. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. Speidl WS; Zeiner A; Nikfardjam M; Geppert A; Jordanova N; Niessner A; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K J Am Coll Cardiol; 2005 Jan; 45(1):30-4. PubMed ID: 15629369 [TBL] [Abstract][Full Text] [Related]
14. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters. Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650 [TBL] [Abstract][Full Text] [Related]
15. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease. Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383 [TBL] [Abstract][Full Text] [Related]
16. Sex differences in the determinants of fibrinolytic activity. MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046 [TBL] [Abstract][Full Text] [Related]
17. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Jurado M; Páramo JA; Gutierrez-Pimentel M; Rocha E Thromb Haemost; 1992 Nov; 68(5):516-20. PubMed ID: 1455397 [TBL] [Abstract][Full Text] [Related]
18. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Erem C Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of t-PA, PAI-2, IL-1beta and PGE(2) in gingival crevicular fluid of rheumatoid arthritis patients with periodontal disease. Biyikoğlu B; Buduneli N; Kardeşler L; Aksu K; Oder G; Kütükçüler N J Clin Periodontol; 2006 Sep; 33(9):605-11. PubMed ID: 16856901 [TBL] [Abstract][Full Text] [Related]
20. Fibrinolytic activity in multiple myeloma. Yağci M; Sucak GT; Haznedar R Am J Hematol; 2003 Dec; 74(4):231-7. PubMed ID: 14635202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]